Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
2020 ◽
2014 ◽
Vol 6
(236)
◽
pp. 236ra62-236ra62
◽
2017 ◽
Vol 233
(3)
◽
pp. 1796-1811
◽
2007 ◽
Vol 29
(11)
◽
pp. 2289-2308
◽